Veracyte, Inc. Expands Operations Campus-Research Laboratory In South San Francisco, California
01/08/2016
The company secured at 10-year lease with plans to accommodate new, state-of-the art R&D and CLIA laboratories, as well as offices for the approximately 120 employees based in the company's corporate location. To accommodate future growth, the company also secured expansion rights, enabling it to procure additional square footage in the same building during 2017 and 2019 as needed.
The new space more than doubles the space Veracyte currently occupies, in order to accommodate the company's strong growth as it offers genomic tests designed to improve disease diagnosis, thus helping patients avoid unnecessary surgeries and taking costs out of the healthcare system.
"This expansion is a direct reflection of Veracyte's success in executing against our business goals," said Bonnie Anderson, Veracyte's President/CEO. "Test volume for our lead product, the Afirma Gene Expression Classifier, increased significantly in 2015, as a result of multiple factors, including expanded reimbursement and inclusion in key industry guidelines.”
“Additionally, we successfully launched the Percepta Bronchial Genomic Classifier last April, and we plan to introduce a second pulmonology product later this year. This significant product growth and expansion has increased our need for additional lab space and employees, while further validating our core mission,” she added.
Most Read
-
-
The Future of the Workforce Is a “Better Normal”
Workforce Q4 2020
-
Trends in Office and Industrial Parks
Q4 2020
-
Recruiting and Retaining Today’s Manufacturing Workforce
Workforce Q4 2020
-
Supply Chain Execs Respond as Pandemic Creates E-Commerce Surge
Q4 2020
-
Another Look at Rural Economies
Q4 2020
-
Cold Storage Is Hotter Than Ever
Q4 2020